Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $618 million, representing a year-over-year growth rate of 28% [25] - For the full fiscal year 2025, revenue reached $2.35 billion, reflecting a year-over-year growth rate of 59% [25] - Adjusted EBITDA for 2025 increased nearly 80% year-over-year to $318 million, with an Adjusted EBITDA margin of 14% [31] - Net income for the full year increased to $128 million, compared to the previous year [34] Business Line Data and Key Metrics Changes - The Hims brand in the US saw over 30% year-over-year revenue growth in 2025, despite a pivot away from generic sexual solutions [26] - The Hers brand continued to display triple-digit revenue growth, accounting for nearly 40% of U.S. revenue [27] - Approximately 65% of subscribers were utilizing a personalized treatment by the end of 2025, with monthly revenue per average subscriber increasing 11% year-over-year to $83 [24][25] Market Data and Key Metrics Changes - International revenue grew almost 400% year-over-year to $134 million, with expectations for this segment to become a more meaningful portion of overall revenue [30] - The company expects at least $200 million in revenue contributions from international markets in 2026, including from the acquisition of Eucalyptus [48] Company Strategy and Development Direction - The company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, focusing on consumer-centric healthcare [22] - Investments in technology and infrastructure are prioritized to enhance personalized care and expand operational capabilities [19][38] - The company plans to deepen its international presence and aims for a unified brand across major markets within the next 1-2 years [54] Management's Comments on Operating Environment and Future Outlook - Management believes the healthcare system must evolve towards a consumer-oriented model, similar to platforms like Netflix and Spotify [6] - The company is confident in its ability to navigate regulatory scrutiny and maintain growth through diverse offerings beyond GLP-1 treatments [56] - Management anticipates strong demand for weight loss solutions and expects subscriber growth to remain robust throughout 2026 [45] Other Important Information - The company has invested over $300 million in facilities over the last three years, expanding its operational footprint to over 1 million square feet [19] - The acquisition of Eucalyptus is expected to enhance the company's international capabilities and contribute significantly to revenue growth [43] Q&A Session Summary Question: What are the long-term priorities for global growth with the acquisition of Eucalyptus? - The company aims to target 10 key markets globally and achieve over $1 billion in incremental international revenue within a few years [54] Question: How will the company manage risks from potential regulatory scrutiny on GLP-1s? - Management emphasizes that the majority of revenue comes from offerings outside of weight loss and plans to continue expanding its diverse offerings [56]

Company Overview - Zhuozheng Medical has passed the main board listing hearing at the Hong Kong Stock Exchange, with Haitong International and Puyin International as joint sponsors [1] - As of 2024, Zhuozheng Medical is the third largest private mid-to-high-end comprehensive medical service provider in China, holding a market share of 2.0% [1] Industry Growth - The private mid-to-high-end medical service market in China is experiencing rapid growth, with total revenue increasing from RMB 193 billion in 2020 to RMB 426.3 billion in 2024, and is projected to reach RMB 831.4 billion by 2029 [1] Company Operations - As of October 28, 2025, Zhuozheng Medical operates 19 medical service institutions in 10 economically developed cities in China, including 17 clinics and 2 hospitals, and has 5 general clinics in Singapore and Malaysia [1] - The company employs a family medical model that integrates online and offline services, offering specialized services in pediatrics, dentistry, ophthalmology, and dermatology [1] - As of August 31, 2025, the company has 387 full-time doctors with an average of 15 years of practice experience, of which approximately 79% have worked in top-tier hospitals [1]